An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Dose Limiting Toxicities in Part 1 and Part 1A

  Measured over: 4 weeks for Doublet Reginmen and 8 weeks for triplet Regimen

• Safety Related Events in Part 1 and Part 1 A

  Measured over: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)

• Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Thyroid Tests

  Measured over: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)

• Clinical Laboratory Abnormalities in Part 1 and Part 1A: Specific Liver Tests

  Measured over: Assessed from first dose date to 100 days after last dose of study therapy. (Approximately: Part 1: ~ 6.5 Months Part 1A: ~ 5.5 Months)

• Overal Response Rate in Part 1B and Part 2

  Measured over: Approximately up to 30 Months

Changes Tremor has spotted